Overview

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the correct prasugrel dosage to be given to children with sickle cell disease (SCD).
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Collaborators:
Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.
Treatments:
Prasugrel Hydrochloride